147 Alhambra Circle Suite 220 Coral Gables, Florida, 33134 United StatesBetter human disease models: We use iPSCs to build more relevant models of human disease to expand your understanding and de risk drug development: - Specialist human iPSC CRO - Supporting neurodegenerative / neuroinflammatory drug discovery / cardiotoxicity / dermatology / ophthalmology - Extensive library of donor iPSCs including lines from Alzheimers, ALS, FTD, Parkinsons, Huntingtons - Full services from donor sourcing, line reprogramming, differentiation, end assays and compound screening - Advanced human like models for pre-clinical research and classification At Axol Bioscience, we support your pursuit of more effective, safer therapies. Like you, we believe that having more human relevant disease models will expand scientific knowledge and de risk drug development. We use human iPSCs to achieve this and have been doing so since 2006. We use donated cells from patients and iPSC technology to build physiologically relevant in vitro models. We have a special focus on neurodegenerative diseases like Alzheimer’s disease as well as cardiotoxicity to promote drug safety. When working with candidate compounds or novel therapies, our in vitro platforms give you better earlier stage modeling and safety testing and later stage efficacy evaluation and improved patient selection. With these data comes better insights, helping you de-risk projects, reduce costs, and save time during drug development. At Axol Bioscience, we help your science with better models of human disease. Since our merger, the company is Censo Biotechnologies trading as Axol Bioscience. All invoices and documentation should be addressed to "Censo Biotechnologies trading as Axol Bioscience."

B260 Meditrina Babraham Research Campus Cambridge, Cambridge, CB22 3AT United KingdomBetter human disease models: We use iPSCs to build more relevant models of human disease to expand your understanding and de risk drug development: - Specialist human iPSC CRO - Supporting neurodegenerative / neuroinflammatory drug discovery / cardiotoxicity / dermatology / ophthalmology - Extensive library of donor iPSCs including lines from Alzheimers, ALS, FTD, Parkinsons, Huntingtons - Full services from donor sourcing, line reprogramming, differentiation, end assays and compound screening - Advanced human like models for pre-clinical research and classification At Axol Bioscience, we support your pursuit of more effective, safer therapies. Like you, we believe that having more human relevant disease models will expand scientific knowledge and de risk drug development. We use human iPSCs to achieve this and have been doing so since 2006. We use donated cells from patients and iPSC technology to build physiologically relevant in vitro models. We have a special focus on neurodegenerative diseases like Alzheimer’s disease as well as cardiotoxicity to promote drug safety. When working with candidate compounds or novel therapies, our in vitro platforms give you better earlier stage modeling and safety testing and later stage efficacy evaluation and improved patient selection. With these data comes better insights, helping you de-risk projects, reduce costs, and save time during drug development. At Axol Bioscience, we help your science with better models of human disease. Since our merger, the company is Censo Biotechnologies trading as Axol Bioscience. All invoices and documentation should be addressed to "Censo Biotechnologies trading as Axol Bioscience."

Charnock Bradley Building Easter Bush, Roslin, Midlothian EH25 9RG, UK Midlothian, Midlothian, EH25 9RG United KingdomBetter human disease models: We use iPSCs to build more relevant models of human disease to expand your understanding and de risk drug development: - Specialist human iPSC CRO - Supporting neurodegenerative / neuroinflammatory drug discovery / cardiotoxicity / dermatology / ophthalmology - Extensive library of donor iPSCs including lines from Alzheimers, ALS, FTD, Parkinsons, Huntingtons - Full services from donor sourcing, line reprogramming, differentiation, end assays and compound screening - Advanced human like models for pre-clinical research and classification At Axol Bioscience, we support your pursuit of more effective, safer therapies. Like you, we believe that having more human relevant disease models will expand scientific knowledge and de risk drug development. We use human iPSCs to achieve this and have been doing so since 2006. We use donated cells from patients and iPSC technology to build physiologically relevant in vitro models. We have a special focus on neurodegenerative diseases like Alzheimer’s disease as well as cardiotoxicity to promote drug safety. When working with candidate compounds or novel therapies, our in vitro platforms give you better earlier stage modeling and safety testing and later stage efficacy evaluation and improved patient selection. With these data comes better insights, helping you de-risk projects, reduce costs, and save time during drug development. At Axol Bioscience, we help your science with better models of human disease. Since our merger, the company is Censo Biotechnologies trading as Axol Bioscience. All invoices and documentation should be addressed to "Censo Biotechnologies trading as Axol Bioscience."

The Science Village, Chesterford Research Park United Kingdom Cambridge, Cambridgeshire, CB10 1XL United KingdomBetter human disease models: We use iPSCs to build more relevant models of human disease to expand your understanding and de risk drug development: - Specialist human iPSC CRO - Supporting neurodegenerative / neuroinflammatory drug discovery / cardiotoxicity / dermatology / ophthalmology - Extensive library of donor iPSCs including lines from Alzheimers, ALS, FTD, Parkinsons, Huntingtons - Full services from donor sourcing, line reprogramming, differentiation, end assays and compound screening - Advanced human like models for pre-clinical research and classification At Axol Bioscience, we support your pursuit of more effective, safer therapies. Like you, we believe that having more human relevant disease models will expand scientific knowledge and de risk drug development. We use human iPSCs to achieve this and have been doing so since 2006. We use donated cells from patients and iPSC technology to build physiologically relevant in vitro models. We have a special focus on neurodegenerative diseases like Alzheimer’s disease as well as cardiotoxicity to promote drug safety. When working with candidate compounds or novel therapies, our in vitro platforms give you better earlier stage modeling and safety testing and later stage efficacy evaluation and improved patient selection. With these data comes better insights, helping you de-risk projects, reduce costs, and save time during drug development. At Axol Bioscience, we help your science with better models of human disease. Since our merger, the company is Censo Biotechnologies trading as Axol Bioscience. All invoices and documentation should be addressed to "Censo Biotechnologies trading as Axol Bioscience."

147 Alhambra Circle Suite 220 Coral Gables, FL, 33134 United StatesBetter human disease models: We use iPSCs to build more relevant models of human disease to expand your understanding and de risk drug development: - Specialist human iPSC CRO - Supporting neurodegenerative / neuroinflammatory drug discovery / cardiotoxicity / dermatology / ophthalmology - Extensive library of donor iPSCs including lines from Alzheimers, ALS, FTD, Parkinsons, Huntingtons - Full services from donor sourcing, line reprogramming, differentiation, end assays and compound screening - Advanced human like models for pre-clinical research and classification At Axol Bioscience, we support your pursuit of more effective, safer therapies. Like you, we believe that having more human relevant disease models will expand scientific knowledge and de risk drug development. We use human iPSCs to achieve this and have been doing so since 2006. We use donated cells from patients and iPSC technology to build physiologically relevant in vitro models. We have a special focus on neurodegenerative diseases like Alzheimer’s disease as well as cardiotoxicity to promote drug safety. When working with candidate compounds or novel therapies, our in vitro platforms give you better earlier stage modeling and safety testing and later stage efficacy evaluation and improved patient selection. With these data comes better insights, helping you de-risk projects, reduce costs, and save time during drug development. At Axol Bioscience, we help your science with better models of human disease. Since our merger, the company is Censo Biotechnologies trading as Axol Bioscience. All invoices and documentation should be addressed to "Censo Biotechnologies trading as Axol Bioscience."

200 Westboro Road 201 Westboro Road Grafton, MA, 01536 United StatesBetter human disease models: We use iPSCs to build more relevant models of human disease to expand your understanding and de risk drug development: - Specialist human iPSC CRO - Supporting neurodegenerative / neuroinflammatory drug discovery / cardiotoxicity / dermatology / ophthalmology - Extensive library of donor iPSCs including lines from Alzheimers, ALS, FTD, Parkinsons, Huntingtons - Full services from donor sourcing, line reprogramming, differentiation, end assays and compound screening - Advanced human like models for pre-clinical research and classification At Axol Bioscience, we support your pursuit of more effective, safer therapies. Like you, we believe that having more human relevant disease models will expand scientific knowledge and de risk drug development. We use human iPSCs to achieve this and have been doing so since 2006. We use donated cells from patients and iPSC technology to build physiologically relevant in vitro models. We have a special focus on neurodegenerative diseases like Alzheimer’s disease as well as cardiotoxicity to promote drug safety. When working with candidate compounds or novel therapies, our in vitro platforms give you better earlier stage modeling and safety testing and later stage efficacy evaluation and improved patient selection. With these data comes better insights, helping you de-risk projects, reduce costs, and save time during drug development. At Axol Bioscience, we help your science with better models of human disease. Since our merger, the company is Censo Biotechnologies trading as Axol Bioscience. All invoices and documentation should be addressed to "Censo Biotechnologies trading as Axol Bioscience."

Little Chesterford, England, CB10 1XL United KingdomBetter human disease models: We use iPSCs to build more relevant models of human disease to expand your understanding and de risk drug development: - Specialist human iPSC CRO - Supporting neurodegenerative / neuroinflammatory drug discovery / cardiotoxicity / dermatology / ophthalmology - Extensive library of donor iPSCs including lines from Alzheimers, ALS, FTD, Parkinsons, Huntingtons - Full services from donor sourcing, line reprogramming, differentiation, end assays and compound screening - Advanced human like models for pre-clinical research and classification At Axol Bioscience, we support your pursuit of more effective, safer therapies. Like you, we believe that having more human relevant disease models will expand scientific knowledge and de risk drug development. We use human iPSCs to achieve this and have been doing so since 2006. We use donated cells from patients and iPSC technology to build physiologically relevant in vitro models. We have a special focus on neurodegenerative diseases like Alzheimer’s disease as well as cardiotoxicity to promote drug safety. When working with candidate compounds or novel therapies, our in vitro platforms give you better earlier stage modeling and safety testing and later stage efficacy evaluation and improved patient selection. With these data comes better insights, helping you de-risk projects, reduce costs, and save time during drug development. At Axol Bioscience, we help your science with better models of human disease. Since our merger, the company is Censo Biotechnologies trading as Axol Bioscience. All invoices and documentation should be addressed to "Censo Biotechnologies trading as Axol Bioscience."